ObjectiveTo explore the mechanism of paucigranulocytic asthma and to find therapeutic target for paucigranulocytic asthma.MethodsGSE143303 data and platform information were downloaded from GEO. Gene Set Enrichment Analysis were performed to construct positive and negative gene-gene interaction network correlation with paucigranulocytic asthma. Differential expression analysis, pathway commonality analysis were performed with R language.ResultsGSE143303 data set contained 47 endobronchial biopsies from adult (16 cases of paucigranulocytic asthma, 13 cases of healthy control). Compared with control group, the paucigranulocytic asthma group had 115 differential genes set (37 positive and 78 negative). The results of pathway commonality analysis showed that the crosslink existed within the negative gene-gene interaction network correlation with paucigranulocytic asthma. Among these, most of the genes belonged to the protein HLA gene family. Differential expression analysis show that HLA-DQB1, HLA-DRB5 were differential genes and TNFRSF13B was significantly downregulated genes in the intersect genes.ConclusionTNFRSF13B, HLA-DQB1, HLA-DRB5 and regulatory networks associated with them are the crucial factors contributing to paucigranulocytic asthma.
ObjectiveCompare the therapeutic effects of multivessel percutaneous coronary intervention (MV-PCI) and culprit-only revascularization strategy (C-PCI) in percutaneous coronary intervention (PCI) for patients with acute myocardial infarction complicated by cardiogenic shock (AMICS) and multivessel disease (MVD). MethodsThe PubMed, Embase, Cochrane Library, MEDLINE, Web of Science, CENTRAL, CNKI and WanFang Data databases were searched to collect studies comparing C-PCI vs. MV-PCI in patients with AMI and CS from inception to March 2, 2025. Methodological quality of the included studies was assessed using the Newcastle-Ottawa scale (NOS) and the risk of bias (ROB) tool. Meta-analysis was performed using RevMan software (version 5.4.0). ResultsA total of 18 studies (1 randomized controlled trial, 1 post-hoc analysis of a randomized controlled trial, and 16 retrospective observational studies), enrolling 101 693 patients. The results of the observational studies showed that MV-PCI was associated with higher risk of short-term mortality (OR=1.13, 95%CI 1.01 to 1.25, P=0.03), renal replacement therapy (OR=1.41, 95%CI 1.32 to 1.50, P<0.00001), and cerebrovascular accident events (OR=1.21, 95%CI 1.10 to 1.33, P=0.0001). No significant difference was observed in long-term mortality (OR=0.93, 95%CI 0.74 to 1.16, P=0.51), recurrent myocardial infarction (OR=1.16, 95%CI 0.97 to 1.39, P=0.10), repeat revascularization events (OR=0.83, 95%CI 0.58 to 1.20, P=0.33) and bleeding event rates (OR=1.01, 95%CI 0.71 to 1.34, P=0.97) between groups. The results remained consistent after adding the only randomized trial.ConclusionsIn patients with AMICS and concomitant MVD, C-PCI provides comparable survival benefits to MV-PCI and is associated with a reduced risk of all-cause mortality, cerebrovascular events, and the need for renal replacement therapy.
